Abstract 19941: Clinical and Demographic Characteristics According to Dosage Among New Initiators and/or Switchers From Warfarin Non-valvular Atrial Fibrillation Patients on Apixaban, Dabigatran and Rivaroxaban
| Autor: | William Petkun, Shital Kamble, Jack Mardekian, Cristina Masseria, Yaniv Ravee, Gregory Y.H. Lip, Phatak Hemant, Ping G. Tepper, Younous Abdulsattar |
|---|---|
| Rok vydání: | 2015 |
| Předmět: | |
| Zdroj: | Circulation. 132 |
| ISSN: | 1524-4539 0009-7322 |
| DOI: | 10.1161/circ.132.suppl_3.19941 |
| Popis: | Background: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia [1-3] with increasing prevalence in the aging [4]. With the advent of the three NOACs including apixaban, dabigatran and rivaroxaban, it is important to characterize patients prescribed with the different dosage of treatment in the real-world setting. Purpose: To describe the baseline clinical and demographic characteristics of NVAF patients on apixaban (5 mg vs 2.5 mg -reduced), rivaroxaban (20mg vs reduced dose: 15 mg or 10 mg), and dabigatran (150 mg vs reduced 75 mg). Methods: A retrospective cohort study was conducted using MarketScan Earlyview ® data. NVAF patients ≥18 years with a minimum of 1 year baseline period were included if they either received a NOAC or were switched from warfarin to NOAC during the study period of Jan 1, 2013 to October 31, 2014. Results: For NVAF patients , the majority of the patients were on the standard dosage (Table 1). Similarly for each NOAC, patients using low dosage versus standard dosage were older, had a greater stroke risk, had a prior history of bleeding and were sicker in terms of presence of congestive heart disease, renal disease and Charleson comorbidity index. Patients switching from warfarin had on average a large number of missing dosage data, and if switching to apixaban were more likely to be prescribed the reduced dose than the 5 mg dose. No clear trend was observed for patients switching to dabigatran or rivaroxaban. More than 15% Apixaban and rivaroxaban patients switched from warfarin while only Conclusion: AF patient initiated with standard dosages of NOACs had better clinical and demographic characteristics than patients initiated with reduced dosages of NOAC. Table 1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|